Download PDF
Planta Med 2017; 83(03/04): 261-267
DOI: 10.1055/s-0042-113386
Biological and Pharmacological Activity
Original Papers
Georg Thieme Verlag KG Stuttgart · New York

Peltatoside Isolated from Annona crassiflora Induces Peripheral Antinociception by Activation of the Cannabinoid System

Cristina da Costa Oliveira
1   Department of Pharmacology, Institute of Biological Sciences, Federal University of Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil
,
Clarice de Carvalho Veloso
1   Department of Pharmacology, Institute of Biological Sciences, Federal University of Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil
,
Renata Cristina Mendes Ferreira
1   Department of Pharmacology, Institute of Biological Sciences, Federal University of Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil
,
Gisele Avelar Lage
2   Department of Chemistry, Institute of Exact Sciences, UFMG, Belo Horizonte, Minas Gerais, Brazil
,
Lúcia Pinheiro Santos Pimenta
2   Department of Chemistry, Institute of Exact Sciences, UFMG, Belo Horizonte, Minas Gerais, Brazil
,
Igor Dimitri Gama Duarte
1   Department of Pharmacology, Institute of Biological Sciences, Federal University of Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil
,
Thiago Roberto Lima Romero
1   Department of Pharmacology, Institute of Biological Sciences, Federal University of Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil
,
Andrea de Castro Perez
1   Department of Pharmacology, Institute of Biological Sciences, Federal University of Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil
› Author Affiliations
Further Information

Publication History

received 19 January 2016
revised 07 July 2016

accepted 17 July 2016

Publication Date:
30 August 2016 (online)

Also available at
    Permissions and Reprints

Abstract

Peltatoside is a natural compound isolated from leaves of Annona crassiflora Mart., a plant widely used in folk medicine. This substance is an analogue of quercetin, a flavonoid extensively studied because of its diverse biological activities, including analgesic effects. Besides, a previous study suggested, by computer structure analyses, a possible quercetin-CB1 cannabinoid receptor interaction. Thus, the aim of this work was to assess the antinociceptive effect of peltatoside and analyze the cannabinoid system involvement in this action. The mouse paw pressure test was used and hyperalgesia was induced by intraplantar injection of carrageenan (200 µg/paw). All used drugs were administered by intraplantar administration in Swiss male mice (n = 6). Peltatoside (100 µg/paw) elicited a local inhibition of hyperalgesia. The peripheral antinociceptive action of peltatoside was antagonized by the CB1 cannabinoid antagonist AM251 (160 µg/paw), but not by CB2 cannabinoid antagonist AM630 (100 µg/paw). In order to assess the role of endocannabinoids in this peripheral antinociceptive effect, we used (i) [5Z,8Z,11Z,14Z]-5,8,11,14-eicosatetraenyl-methyl ester phosphonofluoridic acid, an inhibitor of anandamide amidase; (ii) JZL184, an inhibitor for monoacylglycerol lipase, the primary enzyme responsible for degrading the endocannabinoid 2-arachidonoylglycerol; and (iii) VDM11, an endocannabinoid reuptake inhibitor. MAFP, JZL184, and VDM11 did not induce antinociception, respectively, at the doses 0.5, 3.8, and 2.5 µg/paw, however, these three drugs were able to potentiate the peripheral antinociceptive effect of peltatoside at an intermediary dose (50 µg/paw). Our results suggest that this natural substance is capable of inducing analgesia through the activation of peripheral CB1 receptors, involving endocannabinoids in this process.

Key words

Annonaceae - Annona crassiflora - Quercetin - peltatoside - cannabinoid - peripheral antinociception
 

  • References

  • 1 Ratter JA, Ribeiro JF, Bridgewater S. The Brazilian Cerrado vegetation and threats to its biodiversity. Ann Bot 1997; 80: 223-230
    CrossrefPubMedGoogle Scholar
  • 2 Correia MP. Dicionário das plantas úteis e espécies exóticas [Dictionary of useful plants and exotic species]. Rio de Janeiro: Ministry of Agriculture; 1926: 747
    Google Scholar
  • 3 Cruz G. Dicionário das plantas úteis do Brasil [Dictionary of useful plants from Brazil]. Rio de Janeiro: Civilização Brasileira S. A.; 1979: 599
    Google Scholar
  • 4 Almeida SP, Silva JA, Ribeiro JF. Aproveitamento alimentar de espécies nativas dos cerrados: araticum, barú, cagaita e jatobá [Food utilization of native species from Cerrado: araticum, barú, cagaitaand jatobá]. 1st ed.. Planaltina: EMBRAPA; 1987: 83
    Google Scholar
  • 5 Lorenzi H, Matos FJA. Plantas medicinais brasileiras: Nativas e exóticas cultivadas [Brazilian medicinal plants: native and exotic cultivated]. Nova Odessa: Plantarum Institute; 2002
    Google Scholar
  • 6 De Mesquita ML, Grellier P, Mambu L, Paula JE, Espindola LS. In vitro antiplasmodial activity of Brazilian Cerrado plants used as traditional remedies. J Ethnopharmacol 2007; 110: 165-170
    CrossrefPubMedGoogle Scholar
  • 7 Vilar JB, Ferreira FL, Ferri PH, Guillo LA, Chen CL. Assessment of the mutagenic, antimutagenic and cytotoxic activities of ethanolic extract of araticum (Annona crassiflora Mart. 1841) by micronucleus test in mice. Braz J Biol 2008; 68: 141-147
    CrossrefPubMedGoogle Scholar
  • 8 Vilar JB, Ferri PH, Chen-Chen L. Genotoxicity investigation of araticum (Annona crassiflora Mart., 1841, Annonaceae) using SOS-Inductest and Ames test. Braz J Biol 2011; 71: 197-202
    CrossrefPubMedGoogle Scholar
  • 9 Lage GA, Medeiros FD, Furtado WD, Takahashi JA, de Souza JD, Pimenta LPS. The first report on flavonoid isolation from Annona crassiflora Mart. Nat Prod Res 2014; 28: 808-811
    CrossrefPubMedGoogle Scholar
  • 10 Filho AW, Filho VC, Olinger L, de Souza MM. Quercetin: further investigation of its antinociceptive properties and mechanisms of action. Arch Pharm Res 2008; 31: 713-721
    CrossrefPubMedGoogle Scholar
  • 11 Kaur R, Singh D, Chopra K. Participation of alpha (2) receptors in the antinociceptive activity of quercetin. J Med Food 2005; 8: 529-532
    CrossrefPubMedGoogle Scholar
  • 12 Naidu PS, Singh A, Kulkarni SK. D2-dopamine receptor and alpha2-adrenoreceptor-mediated analgesic response of quercetin. Indian J Exp Biol 2003; 41: 1400-1404
    PubMedGoogle Scholar
  • 13 Shrinivasan M, Skariyachan S, Aparna V, Kolte VR. Homology modelling of CB1 receptor and selection of potential inhibitor against obesity. Bioinformation 2012; 8: 523-528
    CrossrefPubMedGoogle Scholar
  • 14 Hohmann AG. Spinal and peripheral mechanisms of cannabinoid antinociception: behavioural, neurophysiological and neuroanatomical perspectives. Chem Phys Lipids 2002; 121: 173-190
    CrossrefPubMedGoogle Scholar
  • 15 Walpole MA. Massachusetts Pain Initiative: Pain survey executive summary. Available at. http://masspaininitiative.org/files/MassPI_Pain_Survey_-_Executive_Summary_v3.pdf Accessed February 18, 2016
    PubMedGoogle Scholar
  • 16 Governdale L. Outpatient prescription opioid utilization in the US, years 2000 – 2009. Department of Epidemiology, Office of Surveillance and Epidemiology. Silver Spring, MD: US Food and Drug Administration; 2010
    Google Scholar
  • 17 Braden JB, Fan MY, Edlund MJ, Martin BC, DeVries A, Sullivan MD. Trends in use of opioids by noncancer pain type 2000–2005 among Arkansas Medicaid and HealthCore enrollees: results from the TROUP study. J Pain 2008; 9: 1026-1035
    CrossrefPubMedGoogle Scholar
  • 18 Caudill-Slosberg MA, Schwartz LM, Woloshin S. Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000. Pain 2004; 109: 514-519
    CrossrefPubMedGoogle Scholar
  • 19 Sullivan MD, Edlund MJ, Fan MY, DeVries A, Braden JB, Martin BC. Trends in use of opioids for non-cancer pain conditions 2000–2005 in commercial and Medicaid insurance plans: the TROUP study. Pain 2008; 138: 440-449
    CrossrefPubMedGoogle Scholar
  • 20 Fishbain DA, Cole B, Lewis J, Rosomoff HL, Rosomoff RS. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med 2008; 9: 444-459
    CrossrefPubMedGoogle Scholar
  • 21 Walker JM, Hohmann AG. Cannabinoid mechanisms of pain suppression. Handb Exp Pharmacol 2005; 168: 509-554
    PubMedGoogle Scholar
  • 22 Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006; 58: 389-462
    CrossrefPubMedGoogle Scholar
  • 23 Ashton CH. Adverse effects of cannabis and cannabinoids. Br J Anaesth 1999; 83: 637-649
    CrossrefPubMedGoogle Scholar
  • 24 Anjaneyulu M, Chopra K. Quercetin, a bioflavonoid, attenuates thermal hyperalgesia in a mouse model of diabetic neuropathic pain. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 1001-1005
    CrossrefPubMedGoogle Scholar
  • 25 Valério DA, Georgetti SR, Magro DA, Casagrande R, Cunha TM, Vicentini FT, Vieira SM, Fonseca MJV, Ferreira SH, Cunha FQ, Verri WA. Quercetin reduces inflammatory pain: inhibition of oxidative stress and cytokine production. J Nat Prod 2009; 72: 1975-1979
    CrossrefPubMedGoogle Scholar
  • 26 Martínez AL, González-Trujano ME, Aguirre-Hernández E, Moreno J, Soto-Hernández M, López-Muñoz FJ. Antinociceptive activity of Tiliaamericana var. mexicana inflorescences and quercetin in the formalin test and in an arthritic pain model in rats. Neuropharmacology 2009; 56: 564-571
    CrossrefPubMedGoogle Scholar
  • 27 Erlund I. Review of the flavonoids quercetin, hesperetin, and naringenin. Dietary sources, bioactivities, bioavailability, and epidemiology. Nutr Res 2004; 24: 851-874
    CrossrefPubMedGoogle Scholar
  • 28 Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploration. Nat Rev Drug Discov 2004; 3: 771-784
    CrossrefPubMedGoogle Scholar
  • 29 Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-65
    CrossrefPubMedGoogle Scholar
  • 30 Romero TRL, Pacheco DFP, Duarte IDG. Probable involvement of Ca2+-activated Cl− channels (CaCCs) in the activation of CB1 cannabinoid receptors. Life Sci 2013; 92: 815-820
    CrossrefPubMedGoogle Scholar
  • 31 Romero TR, Resende LC, Guzzo LS, Duarte IDG. CB1 and CB2 cannabinoid receptor agonists induce peripheral antinociception by activation of the endogenous noradrenergic system. Anesth Analg 2013; 116: 463-472
    CrossrefPubMedGoogle Scholar
  • 32 Sañudo-Peña MC, Strangman NM, Mackie K, Walker JM, Tsou K. CB1 receptor localization in rat spinal cord and roots, dorsal root ganglion, and peripheral nerve. Acta Pharmacol Sin 1999; 20: 1115-1120
    PubMedGoogle Scholar
  • 33 Anand U, Otto WR, Sanchez-Herrera D, Facer P, Yiangou Y, Korchev Y, Birch R, Benham C, Bountra C, Chessell IP, Anand P. Cannabinoid receptor CB2 localization an agonist-mediated inhibition of capsaicin responses in human sensory neurons. Pain 2008; 138: 667-680
    CrossrefPubMedGoogle Scholar
  • 34 Beltramo M, Piomelli D. Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol. Neuroreport 2000; 11: 1231-1235
    CrossrefPubMedGoogle Scholar
  • 35 Ortega-Gutiérrez S, Molina-Holgado E, Guaza C. Effect of anandamide uptake inhibition in the production of nitric oxide and in the release of cytokines in astrocyte cultures. Glia 2005; 52: 163-168
    CrossrefPubMedGoogle Scholar
  • 36 Schlosburg JE, Kinsey SG, Lichtman AH. Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation. AAPS J 2009; 11: 39-44
    CrossrefPubMedGoogle Scholar
  • 37 Pacheco DF, Klein A, Perez AC, Pacheco CMF, Francischi JN, Duarte IDG. The µ-opioid receptor agonist morphine, but not agonists at δ- or κ-opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors. Br J Pharmacol 2008; 154: 1143-1149
    CrossrefPubMedGoogle Scholar
  • 38 Ghosh S, Wise LE, Chen Y, Gujjar R, Mahadevan A, Cravatt BF, Lichtman AH. The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model. Life Sci 2013; 92: 498-505
    CrossrefPubMedGoogle Scholar
  • 39 Galdino G, Romero TR, Silva JF, Aquiar DC, de Paula AM, Cruz JS, Parrella C, Piscitelli F, Duarte ID, Di Marzo V, Perez AC. The endocannabinoid system mediates aerobic exercise-induced antinociception in rats. Neuropharmacology 2014; 77: 313-324
    CrossrefPubMedGoogle Scholar
  • 40 Green AF, Young PA. A comparison of heat and pressure analgesiometric methods in rats. Br J Pharmacol Chemother 1951; 6: 572-585
    CrossrefPubMedGoogle Scholar
  • 41 Randall LO, Selitto JJ. A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn Ther 1957; 111: 409-419
    PubMedGoogle Scholar